Parker Institute, BMS and CRI announce partnership to accelerate immuno-oncology research

The Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb Company and the Cancer Research Institute (CRI) today announced a multi-year clinical research collaboration to coordinate and rapidly initiate clinical Immuno-Oncology (I-O) studies across the Parker Institute and CRI networks. Bristol-Myers Squibb will work closely with prominent Parker Institute and CRI scientists and researchers, soliciting clinical research

Continue Reading

Chemists make key advancements to simplify drug design and production

Researchers at Rice University, the University of Texas Southwestern Medical Center and Brigham Young University have discovered a one-step solution to make nitrogen-laden molecular precursors for the preparation of drugs and other bioactive molecules. Research announced this month in Science will simplify the process and cut the cost of creating key nitrogen-containing functional groups for

Continue Reading

Pfizer Publish New Analysis Showing Long Term Therapy Slowed Progression of Rare Neurodegenerative Disease

Pfizer Inc. announced the recent publication of a post-hoc analysis of data from three studies of VYNDAQEL in patients with mild transthyretin familial amyloid polyneuropathy (TTR-FAP). The analysis, which included patients with the Val30Met mutation treated over varying periods of up to 5 and a half years, showed that treatment with VYNDAQEL initiated during the

Continue Reading